Kimberly-Clark to Buy Tylenol Maker Kenvue. Why the Stock Market Hates the Deal.

The firm noted that Kimberly-Clark is paying a “significant equity premium” to acquire Kenvue. The deal values Kenvue at $19.25 a share. Even with Monday’s gains, the stock was trading at under $17.